Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Liver concerns scupper Takeda's fasiglifam at Phase III

This article was originally published in Scrip

Executive Summary

Despite the release of promising initial Phase III efficacy data earlier in the year, 2013 has not ended well for Takeda's first-in-class GPR40 agonist fasiglifam (TAK-875), with the company deciding to drop the oral diabetes drug for safety reasons.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC023936

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel